Increasing feasibility and utility of (18)F-FDOPA PET for the management of glioma

Christopher Bell; Nicholas Dowson; Simon Puttick; Yaniv Gal; Paul Thomas; Mike Fay; Jye Smith; Stephen Rose

doi:10.1016/j.nucmedbio.2015.06.001

Increasing feasibility and utility of (18)F-FDOPA PET for the management of glioma

Nucl Med Biol. 2015 Oct;42(10):788-95. doi: 10.1016/j.nucmedbio.2015.06.001. Epub 2015 Jun 9.

Authors

Christopher Bell¹, Nicholas Dowson², Simon Puttick³, Yaniv Gal⁴, Paul Thomas⁵, Mike Fay⁶, Jye Smith⁷, Stephen Rose⁸

Affiliations

¹ CSIRO Preventative Health Flagship, CSIRO Computational Informatics, The Australian e-Health Research Centre, Herston QLD 4029, Australia; The University of Queensland, School of Medicine, St. Lucia QLD 4072, Australia.
² CSIRO Preventative Health Flagship, CSIRO Computational Informatics, The Australian e-Health Research Centre, Herston QLD 4029, Australia.
³ Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St. Lucia QLD 4072, Australia.
⁴ The University of Queensland, Centre for Medical Diagnostic Technologies in Queensland, St. Lucia QLD 4072, Australia.
⁵ Department of Radiation Oncology, Royal Brisbane and Women's Hospital, Herston QLD 4029, Australia.
⁶ The University of Queensland, School of Medicine, St. Lucia QLD 4072, Australia; Genesis Cancer Care, Lake Macquarie Private Hospital, 36 Pacific Highway, Gateshead NSW 2290, Australia; Specialised PET Services Queensland, Royal Brisbane and Women's Hospital, Herston QLD 4029, Australia.
⁷ The University of Queensland, School of Medicine, St. Lucia QLD 4072, Australia; Specialised PET Services Queensland, Royal Brisbane and Women's Hospital, Herston QLD 4029, Australia.
⁸ CSIRO Preventative Health Flagship, CSIRO Computational Informatics, The Australian e-Health Research Centre, Herston QLD 4029, Australia. Electronic address: Stephen.Rose@csiro.au.

PMID: 26162582
DOI: 10.1016/j.nucmedbio.2015.06.001

Abstract

Introduction: Despite radical treatment therapies, glioma continues to carry with it a uniformly poor prognosis. Patients diagnosed with WHO Grade IV glioma (glioblastomas; GBM) generally succumb within two years, even those with WHO Grade III anaplastic gliomas and WHO Grade II gliomas carry prognoses of 2-5 and 2 years, respectively. PET imaging with (18)F-FDOPA allows in vivo assessment of the metabolism of glioma relative to surrounding tissues. The high sensitivity of (18)F-DOPA imaging grants utility for a number of clinical applications.

Methods: A collection of published work about (18)F-FDOPA PET was made and a critical review was discussed and written.

Results: A number of research papers have been published demonstrating that in conjunction with MRI, (18)F-FDOPA PET provides greater sensitivity and specificity than these modalities in detection, grading, prognosis and validation of treatment success in both primary and recurrent gliomas. In further comparisons with (11)C-MET, (18)F-FLT, (18)F-FET and MRI, (18)F-FDOPA has shown similar or better efficacy. Recently synthesis cassettes have become available, making (18)F-FDOPA more accessible.

Conclusions: According to the available data, (18)F-FDOPA PET is a viable radiotracer for imaging and treatment planning of gliomas.

Advances in knowledge and implication for patient care: (18)F-FDOPA PET appears to be a viable radiopharmaceutical for the diagnosis and treatment planning of gliomas cases, improving on that of MRI and (18)F-FDG PET.

Keywords: (18)F-FDOPA; Dopamine; Glioblastoma; Glioma; Infiltration; PET.

Publication types

Meta-Analysis
Research Support, Non-U.S. Gov't
Review

MeSH terms

Dihydroxyphenylalanine / analogs & derivatives*
Feasibility Studies
Glioma / diagnostic imaging*
Glioma / pathology
Glioma / radiotherapy
Glioma / surgery
Humans
Neoplasm Grading
Positron-Emission Tomography / methods*
Radiotherapy Planning, Computer-Assisted

Substances

fluorodopa F 18
Dihydroxyphenylalanine